Comparative Pharmacology
Head-to-head clinical analysis: DURAQUIN versus SORINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURAQUIN versus SORINE.
DURAQUIN vs SORINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Quinidine is a class Ia antiarrhythmic agent that blocks sodium channels, slowing phase 0 depolarization, prolongs the action potential duration, and increases the effective refractory period. It also exhibits anticholinergic and negative inotropic effects.
Selective beta-1 adrenergic receptor antagonist; decreases cardiac output, heart rate, and blood pressure.
Quinidine sulfate 324 mg orally every 8-12 hours, adjusted based on serum quinidine levels.
5 mg orally once daily, increased after 4 weeks to 10 mg orally once daily if tolerated and needed.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in adults with normal renal and hepatic function. Clinically, dose adjustment may be needed in renal impairment (half-life prolonged to up 18 hours) or hepatic impairment.
4-6 hours in healthy adults; prolonged to 12-18 hours in severe renal impairment (CrCl <30 mL/min).
Primarily hepatic metabolism (90-95%) to inactive metabolites, with renal excretion of unchanged drug <5% and metabolites. Fecal elimination accounts for <5% due to biliary excretion of metabolites.
Renal (80% unchanged) and biliary (15% as metabolites); 5% fecal.
Category C
Category C
Antiarrhythmic
Antiarrhythmic